Elo Mutual Pension Insurance Co Sells 818 Shares of Hologic, Inc. (NASDAQ:HOLX)

Elo Mutual Pension Insurance Co reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 21,111 shares of the medical equipment provider’s stock after selling 818 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Hologic were worth $1,567,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of HOLX. Price T Rowe Associates Inc. MD lifted its holdings in shares of Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the last quarter. Black Creek Investment Management Inc. lifted its stake in Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Hologic by 5.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after purchasing an additional 124,739 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Hologic by 4.0% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after buying an additional 87,176 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Hologic by 117.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock worth $154,598,000 after buying an additional 1,168,564 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of Hologic stock opened at $81.39 on Friday. The business has a 50-day moving average price of $80.74 and a two-hundred day moving average price of $77.05. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The company has a market cap of $18.99 billion, a P/E ratio of 41.53, a PEG ratio of 2.53 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter last year, the firm posted $0.93 earnings per share. The firm’s revenue was up 2.7% on a year-over-year basis. As a group, analysts anticipate that Hologic, Inc. will post 4.09 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on HOLX shares. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday. Evercore ISI boosted their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Tuesday, July 30th. JPMorgan Chase & Co. upped their price objective on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research report on Friday, August 16th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.60.

Insider Buying and Selling

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock valued at $1,469,973 over the last ninety days. 1.75% of the stock is owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.